A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients

Trial Profile

A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Emotional lability
  • Focus Therapeutic Use
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 09 May 2016 Planned End Date changed from 1 Sep 2017 to 1 Jun 2016.
    • 09 May 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2016.
    • 09 May 2016 Status changed from recruiting to discontinued due to difficulty in recruiting suitable nursing home patients and not possible to achieve the study goals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top